Institutional Biosafety Committee Binghamton University

Meeting Minutes of October 30, 2026, approved November 12, 2026

Attendees: Kelly Donovan, Karin Sauer, Lori Cole, Cláudia N. H. Marques, Florence Varodayan, James Sobel, Jeff Oliver

Excused: Suzin Webb, Sha Jin

Recording secretaries: Nancy Lewis (non-voting) and Stephen Kamper (non-voting)

I. Meeting was called to order on October 30, 2026 at 1:02 pm.

II. Motion to approve the agenda was made by K. Sauer, seconded by J. Donovan and passed without dissent

III. Motion to approve the minutes of the August 31, 2026 meeting was made by K. Sauer, seconded by J. Sobel and passed without dissent.

IV. Amendment 202600000028 for 020BIO00000173: The Role of the Hippocampal Vasculature in Vascular Cognitive Impairment and Dementia (PI-A. Chapman).

- C. N.H. Marques provided an overview of the protocol and opened it to the IBC for discussion.
- K. Sauer confirmed with the PI that she does not intend to use any helper plasmids.
- L. Cole confirmed the PI is currently observing the protocol for safe handling, storage and use of controls in the animal laboratory.
- C. N. H. Marques recommended approval with a statement (condition) that the procedures, controls and transport methods for the safe handling of the BSL-1 AAV proposed be conveyed including that no helper plasmids are being used, plasmids are non-replicative, and the final product is what is being administered.
- C. N. H. Marques motioned to approve the amendment and K. Sauer seconded the motion. The amendment was approved without dissent. The amendment was approved by IBC with the vote of 7 for, 0 against, 2 absent, 0 abstain.

V. Protocol 020BIO00000290: Neuromodulation and recording (PI-S. Rao) was reviewed for renewal.

- C. N.H. Marques provided an overview of the protocol and opened it to the IBC for discussion.

- K. Sauer confirmed with the PI that she does not intend to use oncogenes or toxins to deliver the 3rd generation lentivirus.

- F. Varodayan suggested, as a general comment, that the PIs using multiple viruses state whether or not they intend to co-inject multiple viruses into the same location and if so, to identify such specificity in the protocol. C. N. H. Marques informed that additional supporting documentation template(s) to improve protocol information is under review.

- L. Cole confirmed that the PI, who has another approved Biosafety protocol and associated IACUC protocol, is not currently using lentivirus in vivo.

- L. Cole asked, in general, if the IBC requires CFAs fall under the purview of this IBC to which the BSO responded to the negative to date. C.N. H. Marques suggested that further consideration may be warranted.

- C. N. H. Marques recommended approval with a statement (condition) that the use of lentivirus is only performed invitro. In vivo work with lentivirus can commence in the animal facility once the lab space to handle such work in completed. At that time, an amendment will be required to include processes, revised SOPs, and a D2 table delineating such work.

- K. Sauer moved to approve the protocol with those conditions and K. Donovan seconded the motion. The protocol was approved without dissent. The protocol was approved by IBC with the vote of 7 for, 0 against, 2 absent, 0 abstain.

VI. C. N. H. Marques motioned to adjourn the meeting at 1:49 pm on October 30, 2026. J. Sobel seconded the motion and the meeting closed without dissent.

Prepared by S. Kamper and N. Lewis 11/02/2026